Maria Teresa Greco1, Anna Roberto2, Oscar Corli2, Silvia Deandrea2, Elena Bandieri2, Silvio Cavuto2, Giovanni Apolone2. 1. Maria Teresa Greco, University of Milan; Maria Teresa Greco, Anna Roberto, and Oscar Corli, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Istituto di Ricerche Farmacologiche "Mario Negri," Milan; Silvia Deandrea, European Commission, Joint Research Centre, Ispra; Elena Bandieri, Azienda Unita Sanitaria Locale di Modena, Modena; and Silvio Cavuto and Giovanni Apolone, IRCCS, Arcispedale "S. Maria Nuova," Reggio Emilia, Italy. mariateresa.greco@marionegri.it. 2. Maria Teresa Greco, University of Milan; Maria Teresa Greco, Anna Roberto, and Oscar Corli, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Istituto di Ricerche Farmacologiche "Mario Negri," Milan; Silvia Deandrea, European Commission, Joint Research Centre, Ispra; Elena Bandieri, Azienda Unita Sanitaria Locale di Modena, Modena; and Silvio Cavuto and Giovanni Apolone, IRCCS, Arcispedale "S. Maria Nuova," Reggio Emilia, Italy.
Abstract
PURPOSE: Pain is a frequent symptom in patients with cancer, with substantial impact. Despite the availability of opioids and updated guidelines from reliable leading societies, undertreatment is still frequent. METHODS: We updated a systematic review published in 2008, which showed that according to the Pain Management Index (PMI), 43.4% of patients with cancer were undertreated. This review included observational and experimental studies reporting negative PMI scores for adults with cancer and pain published from 2007 to 2013 and retrieved through MEDLINE, Embase, and Google Scholar. To detect any temporal trend and identify potential determinants of undertreatment, we compared articles published before and after 2007 with univariable, multivariable, and sensitivity analyses. RESULTS: In the new set of 20 articles published from 2007 to 2013, there was a decrease in undertreatment of approximately 25% (from 43.4 to 31.8%). In the whole sample, the proportion of undertreated patients fell from 2007 to 2013, and an association was confirmed between negative PMI score, economic level, and nonspecific setting for cancer pain. Sensitivity analysis confirmed the robustness of results. CONCLUSION: Analysis of 46 articles published from 1994 to 2013 using the PMI to assess the adequacy of analgesic therapy suggests the quality of pharmacologic pain management has improved. However, approximately one third of patients still do not receive pain medication proportional to their pain intensity.
PURPOSE:Pain is a frequent symptom in patients with cancer, with substantial impact. Despite the availability of opioids and updated guidelines from reliable leading societies, undertreatment is still frequent. METHODS: We updated a systematic review published in 2008, which showed that according to the Pain Management Index (PMI), 43.4% of patients with cancer were undertreated. This review included observational and experimental studies reporting negative PMI scores for adults with cancer and pain published from 2007 to 2013 and retrieved through MEDLINE, Embase, and Google Scholar. To detect any temporal trend and identify potential determinants of undertreatment, we compared articles published before and after 2007 with univariable, multivariable, and sensitivity analyses. RESULTS: In the new set of 20 articles published from 2007 to 2013, there was a decrease in undertreatment of approximately 25% (from 43.4 to 31.8%). In the whole sample, the proportion of undertreated patients fell from 2007 to 2013, and an association was confirmed between negative PMI score, economic level, and nonspecific setting for cancer pain. Sensitivity analysis confirmed the robustness of results. CONCLUSION: Analysis of 46 articles published from 1994 to 2013 using the PMI to assess the adequacy of analgesic therapy suggests the quality of pharmacologic pain management has improved. However, approximately one third of patients still do not receive pain medication proportional to their pain intensity.
Authors: Amye J Tevaarwerk; Ju-Whei Lee; Abigail Terhaar; Mary E Sesto; Mary Lou Smith; Charles S Cleeland; Michael J Fisch Journal: Cancer Date: 2015-12-21 Impact factor: 6.860
Authors: Christopher J Coyne; Cielito C Reyes-Gibby; Danielle D Durham; Beau Abar; David Adler; Aveh Bastani; Steven L Bernstein; Christopher W Baugh; Jason J Bischof; Corita R Grudzen; Daniel J Henning; Matthew F Hudson; Adam Klotz; Gary H Lyman; Troy E Madsen; Daniel J Pallin; Juan Felipe Rico; Richard J Ryan; Nathan I Shapiro; Robert Swor; Charles R Thomas; Arvind Venkat; Jason Wilson; Sai-Ching Jim Yeung; Jeffrey M Caterino Journal: Support Care Cancer Date: 2021-01-22 Impact factor: 3.603
Authors: Morten Thronæs; Trude Rakel Balstad; Cinzia Brunelli; Erik Torbjørn Løhre; Pål Klepstad; Ola Magne Vagnildhaug; Stein Kaasa; Anne Kari Knudsen; Tora Skeidsvoll Solheim Journal: Support Care Cancer Date: 2019-07-09 Impact factor: 3.603
Authors: R López López; C Camps Herrero; P Khosravi-Shahi; V Guillem Porta; A Carrato Mena; J Garcia-Foncillas; J J Cruz Hernández; P Gascón Vilaplana; A Antón Torres; E Diaz-Rubio; M Feyjoo Saus; E Aranda Aguilar Journal: Clin Transl Oncol Date: 2017-10-03 Impact factor: 3.405